Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
This trial is active, not recruiting.
|Conditions||parkinson's disease, quality of life|
|Sponsor||pico-tesla Magnetic Therapies, LLC|
|Start date||March 2009|
|End date||January 2012|
|Trial size||72 participants|
|Trial identifier||NCT00863226, 09026-01|
The purpose of this study is to see if a device called the Resonator can help to improve aspects of health and quality of life that are relevant to patients with Parkinson's disease.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Aurora, CO||University of Colorado Health Sciences Center||no longer recruiting|
|Denver, CO||Mile High Research Center||no longer recruiting|
|Englewood, CO||CNI Movement Disorders Center||no longer recruiting|
|St. Petersbury, FL||Suncoast Neuroscience Associates||no longer recruiting|
|Tampa, FL||University of South Florida||no longer recruiting|
|Novi, MI||Detroit Clinical Research Center||no longer recruiting|
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, investigator, outcomes assessor)|
Change in PDQ-39 single index score
time frame: 8 weeks
Male or female participants from 30 years up to 85 years old.
Inclusion Criteria: - Idiopathic Parkinson's Disease - Stable optimized anti-PD drugs for at least 4 weeks - PDQ-39 Summary Index between 15 and 45 - Ambulatory - Willing to maintain regular medication regime throughout study - Able to abstain from starting in new treatments to improve PD symptoms during course of study. - No prior surgical interventions for Parkinson's Disease - Non-demented - Minimum of 30 years of age, but not older than 85 - Capable of giving full written consent Exclusion Criteria: - Atypical Parkinsonism such as progressive supranuclear palsy, multiple system atrophy, CBDG etc. - Subjects may not have any of the following: active brain tumor, strokes, hydrocephalus, any other neurologic or non-neuro problem which may affect symptomatic expression of patients parkinsonism. - Consumption of medications that can produce drug induced parkinsonism - Chronic pain not associated with PD - Current or past history of major psychiatric disturbance - No typical or non-typical anti-psychotics for treatment of drug induced psychosis. - Chronic fatigue - Epilepsy or history of epilepsy - Seizures or taking medication for epilepsy - HIV or other autoimmune disorders - History of ECT - Uncontrolled hypertension - Advanced pulmonary disease - Unstable cardiac disease - Prior surgical interventions for Parkinson's disease - Prosthetics or implants comprised of ferrous metals - Pacemaker, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain - Pregnant, breast feeding or planning pregnancy prior to study end - Dementia, developmental disability, psychiatric disorder or other cognitive impairment - Any significant medical condition that may require alteration of medical therapy during the study, or major medical condition which may interfere with the study activity.
|Official title||A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol|
|Principal investigator||Rajeev Kumar, MD|
|Description||This clinical trial will evaluate a new non-invasive, non-significant risk, device therapy as an adjuvant symptomatic treatment for some of the signs and or symptoms of Parkinson's Disease (PD). The device utilizes patented technology involving extremely low level electromagnetic fields.|
Call for more information